Saturday 17 October 2026
Export DTIL’s income statement to Excel — free account
Precision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024. In the quarter to June 2026, revenue grew 37,272.4%, EPS grew 40.9%, free cash flow grew 33.7% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.77
0.40
−6.48%
Follow DTIL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
93.46 | 1.56 | 3.01 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(4.27) | (4.74) | (11.35) | — | |
P/B ratio |
3.92 | 0.58 | 1.78 | — | |
Price to Tangible BV |
4.17 | 0.59 | 1.81 | — | |
EV/Sales |
61.23 | (1.16) | 1.26 | — | |
EV/EBITDA |
0.00 | 0.80 | 0.00 | — | |
EV/Operating CF |
(0.58) | 0.60 | (0.97) | — | |
EV/FCF |
(0.58) | 0.60 | (0.96) | — | |
Quick Ratio |
2.99 | 12.97 | 13.56 | 12.26 | |
Current Ratio |
3.45 | 13.32 | 14.02 | 12.82 | |
Net Debt/EBITDA |
1.11 | (7.07) | 9.34 | 3.51 | |
Debt/Assets |
23.93% | 14.51% | 15.58% | 17.81% | |
Debt/Equity |
1.35 | 0.24 | 0.29 | 0.50 | |
Asset Turnover |
0.01 | 0.24 | 0.34 | 0.00 | |
Operating CF/Net income |
0.70 | (0.56) | 0.65 | 0.41 | |
Capex/Depreciation |
0.04 | (0.48) | (0.18) | 0.00 | |
Interest Coverage |
(57.09) | 35.94 | (29.18) | (63.87) | |
Research and Development Expense of Revenue |
102,707.69% | 42.29% | 120.96% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
56,369.23% | 21.14% | 62.77% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
18,353.85% | 5.97% | 14.29% | 0.00% | |
Graham Net Nets |
(0.39) | 1.06 | 0.30 | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(152.17%) | (123.08%) | (66.55%) | — | |
Free Cash Flow Yield |
(112.95%) | (124.59%) | (43.67%) | — | |
Revenue per Share |
0.00 | 2.67 | 0.44 | 0.00 | |
Operating CF per Share |
(1.29) | (0.88) | (0.48) | (0.52) | |
Capex per Share |
0.00 | (0.03) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.29) | (0.90) | (0.49) | (0.52) | |
Cash per Share |
3.80 | 9.01 | 4.11 | 3.39 | |
Shareholders Equity per Share |
1.41 | 7.19 | 3.09 | 1.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.41 | 7.19 | 3.09 | 1.75 | |
Free Cash Flow |
(15.25) | (11.57) | (12.05) | (13.44) | |
Working Capital |
36.71 | 109.83 | 100.94 | 84.41 | |
Capital Expenditures |
0.02 | (0.32) | (0.11) | 0.00 | |
Net Current Asset Value |
(25.17) | 56.57 | 40.90 | 10.92 | |
EV/EBIT |
0.00 | 0.76 | 0.00 | — | |
Capex to Sales |
(1.31) | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.11 | — | 2.09 | — | |
Average Payables |
1.15 | 0.80 | 0.93 | 0.97 | |
Average Assets |
123.38 | 145.40 | 134.15 | 117.42 | |
Average Common Equity |
40.75 | 74.32 | 62.72 | 39.67 |
Columns are period end dates